Report Description Table of Contents How Is the Global Craniopharyngioma Treatment Market Evolving Across Surgical, Radiation, and Targeted Therapeutic Approaches? The increasing use of specialized brain tumor surgery, radiation therapy, and long-term hormone replacement is shaping the global Craniopharyngioma Treatment Market. Treatment requirements vary according to tumor size, location, recurrence risk, and hormonal complications, influencing surgical approaches, radiation therapy decisions, and ongoing medical care. According to Strategic Market Research, the Global Craniopharyngioma Treatment Market was estimated at USD 252.58 million in 2025 and is projected to reach USD 365.58 million by 2032, growing at a CAGR of 5.4% during 2026–2032. Continued demand for advanced neurosurgical procedures, treatment of recurring tumors, and lifelong hormone management supports market growth. According to the Central Brain Tumor Registry of the United States (CBTRUS), approximately 1,629 children and teenagers aged 0–19 years were estimated to be living with craniopharyngioma in the United States in 2025. These patients require specialized medical care, including brain surgery, hormone treatment, and regular checkups. This highlights the continued demand for hospitals and doctors specializing in rare brain tumors. A 2026 review of craniopharyngioma treatment reported approximately 338–350 new patients diagnosed annually in the United States. Globally, the disease affects approximately 0.5–2 people per million each year. These figures show the need for specialized treatment facilities to care for newly diagnosed patients. A 2026 US study published in Neurosurgery examined 483 patients who underwent brain tumor surgery at 16 hospitals. Among them, 360 patients received surgery for the first time, while 123 underwent surgery because their tumors had returned. This shows that some patients require additional operations, creating continued demand for specialized brain surgery. A 2026 South Korean study published in the Journal of Neurosurgery examined 225 patients who underwent 269 surgeries. The study found that tumors returned within five years in 27.9% of cases. These findings show why patients need regular monitoring after surgery and why some may require further treatment. Which Subsegments Are Leading and Emerging as the Fastest-Expanding Opportunities in the Global Craniopharyngioma Treatment Market? By Treatment Type: Surgery Leads as Targeted Therapies Expand Treatment Options Largest Subsegment: Surgery Surgery remains the primary treatment approach in the Craniopharyngioma Treatment Market, accounting for an estimated 58.5% market share, equivalent to USD 147.76 million in 2025, with a projected CAGR of 4.65% during 2026–2032. Surgical intervention plays a central role in managing craniopharyngiomas, rare, benign brain tumors located near the pituitary gland and hypothalamus. Its leading position is supported by the widespread use of surgical resection to remove tumor tissue, relieve pressure on surrounding brain structures, and improve long-term disease management. Fastest-Growing Subsegment: Targeted Therapy Targeted therapy accounted for approximately 12.0% of the market, valued at USD 30.31 million in 2025, and is projected to register the fastest CAGR of 9.85% during 2026–2032. Targeted therapies, particularly BRAF and MEK inhibitors for BRAF-mutated papillary craniopharyngiomas, are gaining clinical importance by shrinking tumors and facilitating less invasive treatment approaches. Their ability to reduce the extent of high-risk surgery and radiation exposure near critical structures, including the hypothalamus and optic nerves, supports growing clinical adoption. opportunities. By Tumor Type: Adamantinomatous Cases Lead as Papillary Precision Treatment Advances Largest Subsegment: Adamantinomatous Craniopharyngioma Adamantinomatous craniopharyngioma (ACP) accounted for approximately 76.0% of the global Craniopharyngioma Treatment Market, equivalent to USD 191.96 million in 2025, and is projected to grow at a CAGR of 4.85% during 2026–2032. ACP is the predominant craniopharyngioma subtype among children, particularly those aged 5–15 years, with tumors commonly developing in the sellar and suprasellar regions near the pituitary gland and hypothalamus. Its higher clinical prevalence and complex surgical management requirements contribute to its substantial share of overall treatment expenditure. Fastest-Growing Subsegment: Papillary Craniopharyngioma Papillary craniopharyngioma accounted for approximately 24.0% of the global Craniopharyngioma Treatment Market, equivalent to USD 60.62 million in 2025, and is projected to register the fastest CAGR of 7.05% during 2026–2032. Occurring predominantly in adults, papillary craniopharyngioma is characterized by distinct genetic alterations, particularly BRAF V600E mutations, which are accelerating the adoption of precision-targeted therapies. Growing clinical interest in BRAF and MEK inhibitors is reshaping treatment strategies, expanding therapeutic options, and supporting a gradual shift toward targeted interventions alongside conventional surgical approaches. By End User: Hospitals Lead as Cancer Centers Expand Multidisciplinary Care Largest Subsegment: Hospitals Hospitals account for approximately 66.0% of the global Craniopharyngioma Treatment Market, valued at USD 166.70 million in 2025, with a projected CAGR of 4.75% during 2026–2032. Their market leadership reflects their multidisciplinary role in diagnosing and treating craniopharyngiomas, rare benign brain tumors located near the pituitary gland and hypothalamus. Hospitals integrate neurosurgery, radiation oncology, endocrinology, and specialized neuroimaging to support comprehensive treatment. Increasing utilization of advanced surgical procedures, precision radiotherapy, and long-term hormonal management strengthens hospitals’ position as primary centers for craniopharyngioma care. Fastest-Growing Subsegment: Cancer Treatment Centers Cancer treatment centers accounted for approximately 12.0% of the global Craniopharyngioma Treatment Market, valued at USD 30.31 million in 2025, and are projected to record the fastest CAGR of 7.25% during 2026–2032. Although craniopharyngiomas are classified as benign (non-cancerous) WHO Grade I brain tumors, specialized cancer treatment centers play a crucial role in managing complex cases. Their multidisciplinary expertise in neurosurgery, radiation oncology, endocrinology, and long-term patient monitoring supports comprehensive treatment, particularly for tumors affecting critical brain structures and hormonal functions. By Geography: North America Leads as Asia-Pacific Expands Specialized Care Largest Regional Subsegment: North America North America dominates the global Craniopharyngioma Treatment Market, accounting for an estimated 39.0% market share, valued at USD 98.51 million in 2025, with a projected CAGR of 4.75% during 2026–2032. Regional leadership is supported by the widespread adoption of multidisciplinary treatment approaches integrating advanced neurosurgical techniques, precision radiation therapies, and emerging targeted medical treatments. Strong specialized healthcare infrastructure, access to experienced neuro-oncology teams, and increasing utilization of minimally invasive surgical procedures further strengthen treatment adoption and improve clinical outcomes across the United States and Canada. Fastest-Growing Regional Subsegment: Asia-Pacific Asia-Pacific accounted for approximately 24.0% of the global Craniopharyngioma Treatment Market, representing USD 60.62 million in 2025, and is projected to register the fastest regional CAGR of 7.85% during 2026–2032. Market expansion is supported by growing adoption of advanced neurosurgical procedures, improved access to specialized neuro-oncology centers, and increasing integration of multidisciplinary treatment approaches. Advances in endoscopic skull-base surgery, precision radiotherapy, and long-term postoperative care across China, Japan, India, and South Korea are strengthening regional treatment capabilities and clinical outcomes. Which Pharmaceutical Companies Are Advancing Targeted Therapies and Precision Treatment Strategies in the Global Craniopharyngioma Treatment Market? F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd. is among the most clinically relevant pharmaceutical companies in the Craniopharyngioma Treatment Market, particularly through its BRAF and MEK inhibitor portfolio. The company's Zelboraf (vemurafenib) and Cotellic (cobimetinib) target molecular signaling pathways associated with BRAF V600E-mutated papillary craniopharyngioma. Approximately 90% of papillary craniopharyngiomas harbor BRAF V600E mutations, making this molecular pathway an important therapeutic target. In a published phase II clinical study involving 16 patients with BRAF-mutated papillary craniopharyngioma, vemurafenib combined with cobimetinib demonstrated a median tumor-volume reduction of approximately 94%, highlighting the potential for substantial tumor shrinkage before surgical intervention or radiation therapy. Roche's established precision-oncology capabilities, including BRAF/MEK inhibition and molecular diagnostics, position the company as an important participant in the development of targeted treatment approaches. However, these medicines are not specifically approved for craniopharyngioma, and Roche's commercial leadership in this rare-disease market has not been established through comparative revenue data. Other Companies and Their Therapeutic Roles: Novartis AG: Its BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) provide a molecularly relevant treatment combination for BRAF V600E-mutated tumors, with potential application in selected papillary craniopharyngioma cases. Merck & Co., Inc.: Its PD-1 inhibitor Keytruda (pembrolizumab) represents an established immuno-oncology technology, although immunotherapy has no established routine clinical role in craniopharyngioma treatment. Day One Biopharmaceuticals, Inc.: Its RAF inhibitor Ojemda (tovorafenib) demonstrates expertise in developing targeted therapies for RAF-altered brain tumors, although its clinical effectiveness specifically in craniopharyngioma remains unestablished. AstraZeneca PLC: Its MEK inhibitor Koselugo (selumetinib) demonstrates expertise in targeting MAPK pathway signaling, providing scientific relevance to research into molecularly driven brain tumors, although its clinical role in craniopharyngioma remains investigational. Analyst Commentary: How Will Targeted Treatment and Safer Surgery Reshape Long-Term Care? The craniopharyngioma treatment market offers significant opportunities in BRAF V600E-targeted therapies, minimally invasive skull-base surgery, and precision radiotherapy. The most important commercial shift is toward reducing treatment-related complications while improving long-term neurological and endocrine outcomes. Molecular profiling, targeted drug combinations, and hypothalamus-sparing techniques are expected to influence treatment decisions and healthcare spending. Expanding access to specialized neurosurgical facilities and multidisciplinary care, particularly in Asia-Pacific, will further shape market opportunities. Craniopharyngioma Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 252.58 Million Revenue Forecast in 2032 USD 365.58 Million Overall Growth Rate CAGR of 5.4% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Tumor Type, By End User, By Geography By Treatment Type Surgery, Radiation Therapy, Targeted Therapy By Tumor Type Adamantinomatous Craniopharyngioma, Papillary Craniopharyngioma By End User Hospitals, Specialty Neurosurgery Centers, Cancer Treatment Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Adoption of advanced skull-base surgery, precision radiotherapy for residual and recurrent tumors, molecular profiling and BRAF-targeted treatment research, expansion of specialized neurosurgical care, recurring treatment and long-term postoperative monitoring requirements Customization Option Available upon request Frequently Asked Question About This Report Q1. How do recurring tumors influence market demand? A1. Tumor recurrence creates additional requirements for imaging, specialist consultations and further treatment. In a South Korean study of 225 patients, tumors returned within five years in 27.9% of cases. Long-term surveillance therefore generates continuing care needs beyond the initial procedure. Q2. Which treatment approach accounts for the largest market share? A2. Surgery leads with an estimated 58.5% share in 2025. Its position reflects the importance of tumor removal and pressure relief in selected patients. Specialist hospitals require advanced visualization, surgical instruments and coordinated postoperative services to deliver this care. Q3. How is molecular testing influencing industry development? A3. Identifying BRAF V600E mutations helps specialists assess targeted treatment options for eligible papillary tumors. This connects molecular diagnostic services with precision-treatment research. Commercial opportunities depend on identifying suitable patients and establishing how targeted medicines fit alongside surgery and radiation. Q4. What factors could limit targeted therapy adoption in the market? A4. The eligible patient population is small and depends on tumor subtype and mutation status. The report notes that the discussed BRAF/MEK medicines are not specifically approved for this condition. Broader adoption will require stronger clinical evidence and access through appropriate treatment pathways. Q5. Why are multidisciplinary providers important to the industry? A5. Patients may need neurosurgery, radiation treatment and ongoing endocrine care from different specialists. Hospitals hold an estimated 66% share in 2025 because they coordinate these services. Providers offering integrated follow-up can address both tumor management and long-term hormonal complications. Q6. What innovations offer promising market opportunities? A6. Endoscopic skull-base surgery and precision radiotherapy offer opportunities to refine treatment around sensitive brain structures. Targeted drug combinations are another developing approach for selected patients. Providers and suppliers are focusing on disease control alongside fewer treatment-related neurological and hormonal complications. Q7. Which region is expected to witness the fastest market growth? A7. Asia-Pacific is projected to record the fastest regional CAGR of 7.85% during 2026–2032. Investment in tertiary hospitals and specialist treatment facilities supports this outlook. China, Japan, India and South Korea offer opportunities through expanding neurosurgical and precision-radiotherapy capabilities. Sources: U.S. National Cancer Institute – Its August 2023 Overview Estimates Approximately 600 New Craniopharyngioma Diagnoses Annually in the United States, Providing Context for Specialized Neurosurgical and Neuro-Oncology Demand NCI – Craniopharyngioma Disease Burden and Emerging Targeted Treatment U.S. National Cancer Institute – Reports a Proton-Therapy Registry Study Involving 84 Children With Craniopharyngioma, Including 63 Treated With Pencil-Beam Scanning, With Estimated Three-Year Overall Survival of 98.2% and Progression-Free Survival of 94.7% NCI – Childhood Craniopharyngioma: Proton Therapy Utilization and Clinical Outcomes U.S. National Cancer Institute – Summarizes a Phase II Study of 94 Patients Aged 12 Months to 21 Years Who Received Proton Therapy Following Individualized Craniopharyngioma Surgery NCI – Surgical Resection Followed by Proton-Beam Radiation in Pediatric Craniopharyngioma U.S. National Cancer Institute – States That Virtually All Patients Undergoing Complete Craniopharyngioma Resection Require Lifelong Pituitary Hormone Replacement, Supporting Recurring Endocrine Care Requirements NCI – Craniopharyngioma Surgery, Hormone Replacement, and Long-Term Monitoring U.S. National Cancer Institute – Reports Tumor Shrinkage in 15 of 16 Patients Receiving Vemurafenib Plus Cobimetinib for BRAF-Mutated Papillary Craniopharyngioma, With Participants Recruited Across Nine Study Sites NCI – Targeted Drug Combination Results in Papillary Craniopharyngioma U.S. FDA – Its Setmelanotide Clinical Review Identifies Craniopharyngioma as the Cause of Acquired Hypothalamic Obesity in 110 of 142 Trial Participants: 73 Assigned to Setmelanotide and 37 to Placebo FDA – IMCIVREE Clinical Review: Craniopharyngioma-Associated Hypothalamic Obesity and Trial Population Roche / Genentech – Supplies the Zelboraf and Cotellic BRAF/MEK Combination Studied in Papillary Craniopharyngioma; Its Established Commercial Indications Should Be Distinguished From Craniopharyngioma Research and Off-Label Use Roche – Cotellic, Zelboraf Combination, and Genentech Development Responsibilities Genentech / Roche – Actemra’s Active Ingredient, Tocilizumab, Is Being Investigated in a Phase II Adamantinomatous Craniopharyngioma Study With Planned Enrollment of 30 Patients ClinicalTrials.gov – Tocilizumab for Progressive or Recurrent Adamantinomatous Craniopharyngioma: NCT05233397 Pfizer – Its MEK Inhibitor Mektovi, or Binimetinib, Is Being Investigated in a Phase II Adamantinomatous Craniopharyngioma Study With Planned Enrollment of 38 Patients ClinicalTrials.gov – Binimetinib for Progressive or Recurrent Adamantinomatous Craniopharyngioma: NCT05286788 Day One Biopharmaceuticals, Now Part of Servier – Is Listed as an Industry Collaborator in the Phase II Tovorafenib Craniopharyngioma Study, Which Has Planned Enrollment of 57 Participants ClinicalTrials.gov – Tovorafenib for Newly Diagnosed or Recurrent Craniopharyngioma: NCT05465174 Rhythm Pharmaceuticals – Announced FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity in Patients Aged Four Years and Older on March 19, 2026, Creating an Additional Treatment Option for Eligible Craniopharyngioma Survivors With This Complication Rhythm – March 2026 FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Rhythm Pharmaceuticals – May 2026 Cross-Country Research on Childhood-Onset Craniopharyngioma Reported Pituitary Hormone Dysfunction in 100%, Thirst and Fluid Imbalance in 87.9%, and Weight Gain in 78.8% of Study Participants Rhythm – 2026 European Congress of Endocrinology: Craniopharyngioma Survivorship and Endocrine Care Burden Rhythm Pharmaceuticals – Announced Japanese Marketing Authorization for IMCIVREE in Acquired Hypothalamic Obesity on August 24, 2026, Relevant to Managing Hypothalamic Complications Following Craniopharyngioma or Its Treatment Rhythm – August 2026 Japanese Approval of IMCIVREE for Acquired Hypothalamic Obesity Table of Contents - Global Craniopharyngioma Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Tumor Type, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Tumor Type, End User, and Region Emerging Treatment Approaches in Surgery, Radiation Therapy, and Targeted Therapy Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Tumor Type, and End User Regional Market Share Analysis Investment Opportunities in the Craniopharyngioma Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Advanced Neurosurgery, Precision Radiotherapy, BRAF and MEK Inhibitors, and Molecular Diagnostics Opportunities in Minimally Invasive Skull-Base Surgery and Hypothalamus-Preserving Treatment Long-Term Endocrine Management and Postoperative Monitoring Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Clinical Characteristics of Craniopharyngioma Role of Neurosurgery, Radiation Therapy, Targeted Treatment, and Hormone Replacement Impact of Tumor Location, Recurrence Risk, and Hormonal Complications on Treatment Decisions Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Market Assessment (2025) Forecast Methodology and Assumptions (2026–2032) Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Clinical Factors Role of Advanced Neurosurgery and Maximal Safe Tumor Resection Adoption of Proton Beam Therapy, Intensity-Modulated Radiation Therapy, and Stereotactic Techniques Molecular Testing for BRAF V600E Mutations and Targeted Treatment Development Recurrent Tumors, Postoperative Monitoring, and Long-Term Hormone Replacement Minimizing Treatment-Related Neurological and Endocrine Complications Access to Specialized Neurosurgical and Neuro-Oncology Facilities Global Craniopharyngioma Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Surgery Radiation Therapy Targeted Therapy Market Analysis by Tumor Type: Adamantinomatous Craniopharyngioma Papillary Craniopharyngioma Market Analysis by End User: Hospitals Specialty Neurosurgery Centers Cancer Treatment Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Leading and Fastest-Growing Subsegments Market Trends and Treatment Developments (2019–2024) Base Year Market Structure and Treatment Adoption (2025) Market Opportunities and Treatment Forecasts (2026–2032) Regional Market Analysis North America Craniopharyngioma Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Tumor Type, and End User Advanced Neurosurgical Procedures and Proton Therapy Infrastructure Molecular Diagnostics and Specialized Pediatric Neurosurgical Services Country-Level Breakdown: United States Canada Europe Craniopharyngioma Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Tumor Type, and End User Specialized Neurosurgical Networks and Multidisciplinary Pituitary Tumor Programs Precision Radiation Technologies and Postoperative Management Country-Level Breakdown: Germany United Kingdom France Italy Rest of Europe Asia-Pacific Craniopharyngioma Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Tumor Type, and End User Expansion of Tertiary Neurosurgical Infrastructure Advanced MRI Diagnostics and Specialized Treatment Facilities Endoscopic Skull-Base Surgery and Precision Radiotherapy Adoption Country-Level Breakdown: China Japan South Korea India Rest of Asia-Pacific Latin America Craniopharyngioma Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Tumor Type, and End User Access to Specialized Neurosurgical Services Radiotherapy Facilities and Complex Brain Tumor Management Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Craniopharyngioma Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Tumor Type, and End User Investment in Advanced Neurosurgical Hospitals Regional Centers of Excellence and Specialized Neuro-Oncology Treatment Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: F. Hoffmann-La Roche Ltd. Novartis AG Merck & Co., Inc. Day One Biopharmaceuticals, Inc. AstraZeneca PLC Novocure Limited Accuray Incorporated Varian Medical Systems Siemens Healthineers Competitive Landscape and Strategic Insights Benchmarking Based on Targeted Therapy Portfolios, Neurosurgical Technologies, Radiation Delivery, Molecular Diagnostics, and Regional Presence Precision-Oncology Research and BRAF/MEK Inhibitor Positioning Advanced Neurosurgical Systems and Skull-Base Procedure Capabilities Proton Beam Therapy, Intensity-Modulated Radiation Therapy, and Stereotactic Treatment Strategies Long-Term Endocrine Management and Multidisciplinary Care Models Emerging Treatment Developments and Clinical Research (2025–2032) Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Evidence and Published Research Reviewed Through 2026 Market Definitions and Segmentation Framework Historical Data Coverage (2019–2024) Base Year Definitions and Assumptions (2025) Forecast Methodology and Assumptions (2026–2032) Regional and Country Coverage List of Tables Market Size by Treatment Type, Tumor Type, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Treatment Type, Tumor Type, and End User (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Pharmaceutical, Neurosurgical, and Radiotherapy Companies BRAF and MEK Inhibitor Research and Targeted Treatment Approaches Neurosurgical Procedures, Radiation Technologies, and Long-Term Endocrine Care Clinical Evidence and Treatment Developments Reviewed Through 2026 List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Tumor Type, and End User (2025 vs. 2032) Global Craniopharyngioma Treatment Ecosystem and Value Chain Analysis Regional Market Trends and Forecasts (2019–2032) Evolution of Surgical, Radiation, and Targeted Therapeutic Approaches BRAF V600E Molecular Targeting and Precision Treatment Pathways Multidisciplinary Care and Long-Term Endocrine Management